Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven

Category	Detail
Condition	Uveitic Macular Edema
Key Mechanisms	Intravitreal anti–interleukin-6 monoclonal antibody
Target Population	Patients with noninfectious uveitic macular edema
Care Setting	Ophthalmology clinics

No sustained intraocular pressure elevations or new cataracts reported with vamikibart.
Over 80% of participants had complete resolution of intraretinal fluid by week 12.
Improvements in visual acuity maintained through 36 weeks in lower dose groups.
No drug-related serious adverse events reported in the DOVETAIL trial.
Current therapies like corticosteroids have significant limitations.

Consider corticosteroids as standard treatment, but evaluate for potential adverse effects.

Corticosteroids are associated with cataract formation and elevated intraocular pressure.

Patients with anterior, intermediate, posterior, and panuveitis.

Vamikibart shows promise in safety and tolerability, but efficacy remains to be established.

Conduct thorough patient assessments prior to initiating treatment.
Monitor for intraocular inflammation and visual outcomes during follow-up.
Consider participation in ongoing clinical trials for access to novel therapies.